key: cord-0897241-a13n3lxx
authors: Liu, Wanbing; Kou, Guomei; Dong, Yaoyu; Zheng, Yaqiong; Ding, Yinjuan; Ni, Wenxu; Wu, Wanlei; Tang, Shi; Xiong, Zhou; Zhang, Ying; Liu, Lei; Zheng, Shangen
title: Clinical application of Chemiluminescence Microparticle Immunoassay for SARS-CoV-2 infection diagnosis
date: 2020-08-01
journal: J Clin Virol
DOI: 10.1016/j.jcv.2020.104576
sha: 924a62ecb3a548da26c3e790c134f6877e70cc0f
doc_id: 897241
cord_uid: a13n3lxx

BACKGROUND: The unsatisfactory accuracy and capacity of real time RT-PCR depends on several unavoidable reasons, which cannot meet the demands for COVID-19 diagnosis. METHODS: 206 serum samples were collected from patients who were treated in the General Hospital of the Central Theater Command of the PLA between January 18 and April 4, 2020. 270 serum samples from healthy blood donors were used as control. IgM and total antibodies (Ab) against SARS-CoV-2 were detected by Chemiluminescence Microparticle Immunoassay (CMIA). RESULTS: Among the 206 patients, the positive rate of IgM and Ab were 149/206 (72.3 %) and 187/206 (90.8 %), respectively. And the specificity of IgM and Ab detection were 99.3 % and 98.9 %, respectively. The sensitivity of CMIA for Ab detection was significantly higher than that of IgM. An increase of the positive rate and S/CO value for detecting IgM and Ab accompanied with the increasing of days post-disease onset (d.p.o.) were observed. The positive rate of Ab detected by CMIA increased rapidly after 7 d.p.o., while that of IgM was obviously increased after 14 d.p.o.. In addition, the age and gender of these patients did not affect the seroconversion and titer of antibodies during the whole course. The disease-severity of patients had no effect on the seroconversion of antibodies. However, the critical patients possessed a much higher antibody titers than the no-critical cases after 14 d.p.o.. CONCLUSIONS: The CMIA can provide important complementation to nucleic acid assay and help to enhance the accuracy and capacity of diagnosis of SARS-CoV-2 infection.

The recent outbreak of coronavirus infectious disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been classified as a global pandemic on March 12, 2020 (1) .The disease rapidly spreads all over the world and results in more than 4,098,000 cases to be infected and over 283,000 deaths up to May 12, 2020 (2) . So far, the number of infected people is still rapidly growing.

To identify infected-patients as early as possible is the first line of epidemic disease control. Currently, laboratory diagnosis of SARS-CoV-2 infection has been predominantly carried out by detecting viral RNA in nasal or pharyngeal swab samples based on real-time reverse transcription polymerase chain reaction (RT-PCR) assay (3, 4) . However, viral loads mainly in lower respiratory tract and specimen collection in upper respiratory tract caused a high false negative rate of RT-PCR diagnosis (5, 6) . Mainly caused by low quality specimen collection, the overall positive rate of RNA testing is estimated to be around 30-60% in COVID-19 patients (7) . Therefore, a rapid and accurate detection method for SARS-CoV-2 infection is urgently needed.

Another most widely used method serological assay is supposedly a powerful approach for timely diagnosis of COVID-19 and detection of antibody against SARS-CoV-2, which was recommended to clinical Commission of China (8) . The serological assays used for diagnosis are mainly based on specific antibodies against SARS-CoV-2 proteins.

Genomic analysis reveals that SARS-CoV-2 has four major structural proteins including Spike (S) protein, Nucleocapsid (N) protein, Envelope (E) protein, and Membrane (M) protein, as well as a number of accessory open reading frame (ORF) proteins (3, 9) . In this study, we evaluated the performance of Chemiluminescence Microparticle Immunoassay (CMIA) which was developed based on recombinant spike protein for detecting IgM and total antibodies against SARS-CoV-2 in human serum.

A total of 206 serum samples from confirmed COVID-19 patients and 270 serum samples from healthy blood donors were tested by CMIA in the study. In addition, the potential influence factors of antibody production were analyzed.

A total of 206 serum samples were collected from patients who were treated in the General Hospital of the Central Theater Command of the People's Liberation Army (PLA) between January 18 and April 4, 2020. One sample was collected from each patient. All the patients were laboratory-confirmed cases with SARS-CoV-2 J o u r n a l P r e -p r o o f infection, who were tested positive for viral RNA by real time RT-PCR assay on pharyngeal swab specimens. Real time RT-PCR was performed using the nucleic acid testing kit (Daan, Guangzhou, China) for SARS-CoV-2 detection as previously described (10) . A patient was categorized as critical case if any of the bellowed clinical scenes appeared: 1) with Acute Respiratory Distress Syndrome or oxygen saturation < 93% and needing mechanical ventilation either invasively or non-invasively; 2) shock; and 3) complication of organ functional failure and need intensive care unit support. A patient did not meet the above criteria was defined as no-critical case. The general information was extracted from electronic medical records. The control serum samples were randomly collected from 270 healthy blood donors who donated blood in May, 2019, in Wuhan, China. The healthy blood donors were healthy people without other infection and autoimmune diseases. One serum sample was collected from each healthy donor. The demographics (including age and gender) of patients and healthy donors were compared, with no significant differences. This study was approved by the Hospital Ethics Committee of the General Hospital of the Central Theater Command of the PLA ([2020]003-1). The written informed consent was waived by the Ethics Commission of the designated hospital for emerging infectious diseases.

The IgM and total antibodies (Ab) against SARS-CoV-2 in serum samples was tested using chemiluminescence microparticle immunoassays. The 

Categorical variables were expressed as the counts, percentages and compared using the chi-square test, while the Fisher exact test was used when the data were limited. Continuous variables were described as the means and standard deviations or medians and interquartile ranges (IQR) values. Independent group tests were applied to continuous variables that were normally distributed; otherwise, the Mann-Whitney test was used. Statistical analyses were performed using SPSS version 22.0. A two-sided Pvalue < 0.05 was considered statistically significant.

The serum samples were collected from 206 admitted hospital patients with 

Among the enrolled patients, 126 (61.1%) were males, and 80 (38.8%) were females. The median age of these patients was 57 years (IQR, 43-68 years), ranging from 17 to 91 years. And 54 patients were critical cases, 152 patients were no-critical cases according to the severity of clinical symptoms as described above all. To study the factors associated to the production of antibodies in COVID-19 patients, we During whole stage of disease onset, no significant differences were observed in the positive rates and S/CO values between males and females for IgM and Ab detection (Table 2) . Similarly, no significant differences were observed between the groups of age less than 60 years and above 60 years for detecting IgM and Ab (Table 3 ). In The study found that the sensitivity of Ab (90.8%) was significantly higher than that of IgM (72.3%). We speculate the difference is due to the relatively high sensitivity of Ab that detected all antibodies (including IgM) and IgM detected immunoglobulin M only. Moreover, that possibly attributed to the double-antigen sandwich assay that used for detecting Ab usually show much higher sensitivity than capture assay that used J o u r n a l P r e -p r o o f for detecting IgM. The positive rate for IgM detected by CMIA was equal to that for IgM detected by recombinant S protein (rS)-based ELISA (165/214, 77.1%) that we evaluated previously (14) . In our previous study (14) , the rS-based ELISA combined (14) . The durations of illness onset for detecting Ab by CMIA were shorter than that by ELISA, which indicates that Ab detected by CMIA can shorten the "window period" for COVID-19 diagnosis compared with that detected by ELISA. The study has reported that the overall RNA positive rate was lower than 70% in COVID-19 patients on the first week post symptoms onset and fall to 50% on the next week (11) . Therefore, the serological assay especially CMIA assay could be an exact complement for RNA detection.

We also investigated the influences of antibody production. In order to exclude the This study demonstrated that the CMIA of serological assay could be an important complementary detection of RNA assay for COVID-19 diagnosis. And CMIA has high sensitivity and specificity for the detection of serum samples, especially the durations from symptom onset to this serological test was more than 7 days. CMIA also takes the advantages of automatic-operation, high-throughput and rapid, but the instrument was costly. This method provides us a flexible choice of serological immunoassays. It should be recommended to apply in the clinical management and epidemiological surveillance. We also found that the age and gender do not affect the production of Investigation, Formal analysis, Resource.

The authors declare that no conflict of interest exists. Table 3 . The effect of age on antibody detection. 

WHO. Coronavirus disease 2019

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Clinical features of patients infected with 2019 novel coronavirus in

Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes

Recent advances and perspectives of nucleic acid detection for coronavirus

Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in

2020-3-4. Notice on the issuance of strategic guidelines for diagnosis and treatment of novel coronavirus infected pneumonia

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients

Antibody responses to SARS-CoV-2 in J

Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients

Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease

Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2

Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis

We appreciate the help from the healthcare workers and volunteers in this study. We J o u r n a l P r e -p r o o f